eFFECTOR Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EFTR research report →
About the company
eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK.
- CEO
- Davide Ruggero
- IPO
- 2021
- Employees
- 14
- HQ
- Solana Beach, CA, US
Price Chart
- Market Cap
- $2.82K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.17
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 3771.56%
- ROIC
- -221.30%
- Revenue
- $0 · -100.00%
- Net Income
- $-35,811,000 · -177.02%
- EPS
- $-16.37 · -108.54%
- Op Income
- $-33,844,000
- FCF YoY
- -13.63%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.40
- Avg Volume
- 1.88K
Get TickerSpark's AI analysis on EFTR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 13, 24 | Loewy Caroline M | other | 800 |
| Jun 13, 24 | Klencke Barbara | other | 800 |
| Jun 13, 24 | Ehrlich Christopher B | other | 800 |
| Jun 13, 24 | Harrington-Smith Kristen | other | 800 |
| Jun 13, 24 | Gallagher Brian M. Jr. | other | 800 |
| Jun 13, 24 | Bhatt Elizabeth | other | 800 |
| May 15, 24 | Byrnes Michael | other | 1,387 |
| May 15, 24 | WORLAND STEPHEN T | other | 1,806 |
| Feb 19, 24 | Loewy Caroline M | other | 2,000 |
| Feb 19, 24 | Bhatt Elizabeth | other | 2,000 |
Our EFTR coverage
Recent articles, reports, and earnings notes.
No research on EFTR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EFTR report →Similar companies
Peers in the same neighborhood.